A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX.
Phase of Trial: Phase IV
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Infliximab (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SWEFOT
- 19 Dec 2016 Results (n=157) assessing multi-biomarker disease activity score in methotrexate inadequate responders, published in the Arthritis and Rheumatology
- 10 Jun 2016 According to a Crescendo Biologics media release results related to multi-biomarker disease activity score measured by VECTRA DA test will be presented at European League Against Rheumatism (EULAR) meeting.
- 10 Jun 2016 Results related to multi-biomarker disease activity score measured by VECTRA DA test published in a Crescendo Biologics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History